A step forward for stem cells and Parkinson’s disease

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler.

I’m upbeat about cell therapy development for Parkinson’s disease, but it has been a marathon. Now two new clinical trial papers published Wednesday in Nature on stem cell-based therapies for Parkinson’s are another step forward.

However, they also highlight remaining challenges and dilemmas, including the optimal doses of cells, the extent of engraftment, and whether to use allogeneic or autologous cells.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans